Antidiabetic agents:Do they hit the right targets?  

作　　者：Yongting Zhao Xiaofang Zhang Haihai Liang Lihong Wang 

机构地区：[1]Department of Endocrinology,the First Affiliated Hospital of Jinan University,Guangzhou 510630,China [2]Department of Endocrinology,The Second Affiliated Hospital of Harbin Medical University,Harbin 150081,China [3]Department of Pharmacology(State-Province Key Laboratories of Biomedicine-Pharmaceutics of China,Key Laboratory of Cardiovascular Research,Ministry of Education),College of Pharmacy,Harbin Medical University,Harbin 150081,China

出　　处：《Frigid Zone Medicine》2022年第4期225-243,共19页寒地医学（英文）

基　　金：supported by the National Natural Science Foundation of China(NSFC)(No.81770809).

摘　　要：Diabetes mellitus(DM)is a progressive metabolic disease characterized by chronic hyperglycemia and caused by different degree of pancreatic islet dysfunction and/or insulin resistance(IR).Long course DM can lead to a variety of macrovascular and microvascular complications which involve artery vessels,heart,kidney,retina,nervous system,etc.In recent years,DM has attracted more and more attention due to its high morbidity and mortality.In addition to achieve effective glycemic control,prevention of complications has also been considered a priority for type 2 diabetes mellitus(T2DM)management.Herein,we provide a comprehensive overview on the pharmacotherapeutics for T2DM and perspectives on the future directions of basic and translational research on anti-diabetic therapy and pharmatheutical development of new drugs.

关 键 词：diabetes mellitus type 2 diabetes mellitus anti-diabetic drugs therapeutic target glycemic control insulin resistance deficient insulin secretion diabetic complications POLYPHARMACOLOGY 

分 类 号：R587.1[医药卫生—内分泌]